Is subclinical hypothyroidism contributing dyslipidemia and insulin resistance in women with polycystic ovary syndrome?

Basit Öğe Kaydı
dc.authorscopusid24075279000
dc.authorscopusid6506061779
dc.authorscopusid23986422400
dc.authorscopusid23968920100
dc.authorscopusid55314067300
dc.authorscopusid55314280200
dc.authorscopusid57197051921
dc.contributor.authorÇelik, Cem
dc.contributor.authorAbalı, Remzi
dc.contributor.authorTaşdemir, Nicel
dc.contributor.authorGüzel, Savaş
dc.contributor.authorYüksel, Aytac
dc.contributor.authorAksu, Erson
dc.contributor.authorYılmaz, Murat
dc.date.accessioned2022-05-11T14:12:27Z
dc.date.available2022-05-11T14:12:27Z
dc.date.issued2012
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.description.abstractWe aimed to analyze lipid parameters and determine the need for a 2-hour oral glucose tolerance test (OGTT) for the identification of IR and impaired glucose tolerance test (IGT) in subclinical hypothyroidism (SCH) women with and without polycystic ovary syndrome (PCOS). 20 patients with PCOS and SCH consisted of Group I and 39 patients with PCOS and normal thyroid function consisted of Group II and 53 healthy women with normal thyroid function consisted of Group III. Triglyceride levels were 143.26 +/- 99.86 mg/dL in group 1 and 88.56 +/- 37.56 mg/dL in group 2 and 83.71 +/- 31.94 mg/dL in group 3 which were statistically significant. Total cholesterol, HDL-cholesterol, LDL-cholesterol were found similar between the groups. Fasting insulin levels were 12.45 +/- 8.62 mu U/mL in group 1 and 8.60 +/- 5.35 mu U/mL in group 2 and 7.04 +/- 3.55 mu U/mL in group 3 which were statistically significant (P = 0.027). HOMA-IR were 2.92 +/- 2.34 in group 1 and 1.95 +/- 1.52 in group 2 and 1.60 +/- 0.86 in group 3 which were statistically significant (P = 0.046). This study showed that women with PCOS and subclinical hypothyroidism should be evaluated for dyslipidemia and Insulin resistance.
dc.identifier.doi10.3109/09513590.2011.650765
dc.identifier.endpage618
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue8en_US
dc.identifier.pmid22329744
dc.identifier.scopus2-s2.0-84863872111
dc.identifier.scopusqualityQ2
dc.identifier.startpage615
dc.identifier.urihttps://doi.org/10.3109/09513590.2011.650765
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5560
dc.identifier.volume28
dc.identifier.wosWOS:000306427700010
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÇelik, Cem
dc.institutionauthorAbalı, Remzi
dc.institutionauthorTaşdemir, Nicel
dc.institutionauthorGüzel, Savaş
dc.institutionauthorYüksel, Aytaç
dc.institutionauthorAksu, Erson
dc.institutionauthorYılmaz, Murat
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofGynecological Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHypothyroidism
dc.subjectinsulin resistance
dc.subjectpolycystic ovary syndrome
dc.subjectThyroid-Stimulating Hormone
dc.subjectGlucose
dc.subjectObesity
dc.subjectDisease
dc.titleIs subclinical hypothyroidism contributing dyslipidemia and insulin resistance in women with polycystic ovary syndrome?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5560.pdf
Boyut:
594.01 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu